The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course?
dc.authorid | Ozakbas, Serkan/0000-0003-2140-4103 | |
dc.authorid | Tütüncü, Melih/0000-0002-9851-7002 | |
dc.authorid | Petek Balcı, Belgin/0000-0001-5190-7380 | |
dc.authorid | Gündüz, Tuncay/0000-0003-4241-0908 | |
dc.authorid | Baba, Cavid/0000-0001-5455-7080 | |
dc.authorid | Demirkiran, Meltem/0000-0002-4649-5315 | |
dc.authorid | şen, sedat/0000-0001-8048-6845 | |
dc.authorwosid | Karabudak, Rana/HJH-2490-2023 | |
dc.authorwosid | Ozakbas, Serkan/V-6427-2019 | |
dc.authorwosid | Tütüncü, Melih/AAF-1702-2021 | |
dc.authorwosid | Kurtuncu, Murat/L-2705-2015 | |
dc.authorwosid | Petek Balcı, Belgin/CAG-6344-2022 | |
dc.authorwosid | Gündüz, Tuncay/G-9598-2013 | |
dc.authorwosid | Sevim, Serhan/KBA-7417-2024 | |
dc.contributor.author | Sen, Sedat | |
dc.contributor.author | Tuncer, Asli | |
dc.contributor.author | Ozakbas, Serkan | |
dc.contributor.author | Uzunkopru, Cihat | |
dc.contributor.author | Baba, Cavid | |
dc.contributor.author | Demir, Serkan | |
dc.contributor.author | Beckmann, Yesim | |
dc.date.accessioned | 2024-06-12T11:09:10Z | |
dc.date.available | 2024-06-12T11:09:10Z | |
dc.date.issued | 2022 | |
dc.department | Trakya Üniversitesi | en_US |
dc.description.abstract | Background: COVID-19 is a multisystemic infection with variables consequences depending on individual and comorbid conditions. The course and outcomes of COVID-19 during neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD) are not clearly known. Objective/methods: The aim of this study was to examine the features and outcomes of COVID-19 infection in NMOSD and MOGAD patients. The patients' demographic and clinical factors, disease modifying treatment (DMT) used and disease information of COVID-19 infection were recorded. Conditions leading to hospitalization and severe exposure to COVID-19 infection were also analyzed. Results: The study included 63 patients from 25 centers. Thirty-two patients (50.8%) belong to AQP-4 seropositive group, 13 (20.6%) and 18 (28.6%) were in MOG-positive and double-seronegative groups, respectively. Risk factors for severe COVID-19 infection and hospitalization were advanced age, high disability level and the presence of comorbid disease. Disease severity was found to be high in double-seronegative NMOSD and low in MOGAD patients. No statistically significant effect of DMTs on disease severity and hospitalization was found. Conclusion: In NMOSD and MOGAD patients, advanced age, high disability and presence of comorbid disease pose risks for severe COVID-19 infection. There was no direct significant effect of DMTs for COVID-19 infection. | en_US |
dc.identifier.doi | 10.1016/j.msard.2021.103399 | |
dc.identifier.issn | 2211-0348 | |
dc.identifier.issn | 2211-0356 | |
dc.identifier.pmid | 35216782 | en_US |
dc.identifier.scopus | 2-s2.0-85122957692 | en_US |
dc.identifier.scopusquality | Q1 | en_US |
dc.identifier.uri | https://doi.org/10.1016/j.msard.2021.103399 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14551/22692 | |
dc.identifier.volume | 58 | en_US |
dc.identifier.wos | WOS:000793561600010 | en_US |
dc.identifier.wosquality | Q2 | en_US |
dc.indekslendigikaynak | Web of Science | en_US |
dc.indekslendigikaynak | Scopus | en_US |
dc.indekslendigikaynak | PubMed | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier Sci Ltd | en_US |
dc.relation.ispartof | Multiple Sclerosis And Related Disorders | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Neuromyelitis Optica Spectrum Disorders | en_US |
dc.subject | Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorders | en_US |
dc.subject | Disease Modifying Treatment | en_US |
dc.subject | Coronavirus | en_US |
dc.subject | SARS-Cov-2 | en_US |
dc.title | The Turkish experience of COVID-19 infection in people with NMOSD and MOGAD: A milder course? | en_US |
dc.type | Article | en_US |